Resistance Development with Tenofovir/FTC vs. AZT/3TC

In a comparative clinical trial, patients receiving tenofovir/FTC were less likely to develop resistance mutations during virologic failure than were those receiving AZT/3TC.

Tenofovir/FTC has become the preferred dual-NRTI combination for initial antiretroviral therapy (ART), based in part on the results of Study 934, which demonstrated the virologic and tolerability advantages of tenofovir/FTC over AZT/3TC (JW AIDS Clin Care Feb 1 2006). Now, in a continued analysis of that study, researchers have investigated the effects of baseline NRTI and NNRTI resistance on treatment response and the patterns of resistance that emerged during treatment failure.

Study 934 was an open-label trial (sponsored by the maker of tenofovir/FTC) in which 509 treatment-naive patients were randomized to receive tenofovir/FTC or AZT/3TC, each together with efavirenz. Participants with virologic failure (19 in the tenofovir/FTC arm and …

Reviewing Authors

Jonathan Z. Li, MD

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Paul E. Sax, MD

Disclosures

Consultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi

Grant/Research SupportNIH; Gilead Sciences; ViiV

Editorial BoardsUpToDate; Clinical Infectious Diseases

Resistance Development with Tenofovir/FTC vs. AZT/3TC

Topics

Reviewing Authors